[HTML][HTML] Comparison between health insurance claims and electronic health records (EHRs) for metastatic non-small-cell lung cancer (NSCLC) patient characteristics …
YC Choi, D Zhang, JE Tyczynski - Drugs-Real World Outcomes, 2021 - Springer
Background The clinical landscape in non-small-cell lung cancer (NSCLC) treatment has
rapidly evolved in recent years. Real-world data (RWD) can provide insights into current …
rapidly evolved in recent years. Real-world data (RWD) can provide insights into current …
Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting
JC Simeone, BL Nordstrom, K Patel, AB Klein - Future Oncology, 2019 - Future Medicine
Aim: To conduct a retrospective analysis of electronic medical record data to understand real-
world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell …
world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell …
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated …
HA Jung, JM Sun, SH Lee, JS Ahn, MJ Ahn, K Park - Lung Cancer, 2020 - Elsevier
Introduction Until the recent approval of immunotherapy after completing concurrent
chemoradiotherapy (CCRT), there has been little progress in treating unresectable stage III …
chemoradiotherapy (CCRT), there has been little progress in treating unresectable stage III …
Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States
LM Hess, ZL Cui, XI Li, C Molife… - Current Medical Research …, 2021 - Taylor & Francis
Objectives Therapeutic advances for the treatment of patients with advanced/metastatic non-
small cell lung cancer (NSCLC) have led to additional options for care. This observational …
small cell lung cancer (NSCLC) have led to additional options for care. This observational …
Characteristics of real‐world metastatic non‐small cell lung cancer patients treated with nivolumab and pembrolizumab during the year following approval
Background Evidence from cancer clinical trials can be difficult to generalize to real‐world
patient populations, but can be complemented by real‐world evidence to optimize …
patient populations, but can be complemented by real‐world evidence to optimize …
Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States
X Zhang, DC Beachler, E Masters, F Liu… - Journal of Managed …, 2022 - jmcp.org
BACKGROUND: The treatment landscape for advanced nonsmall cell lung cancer (NSCLC)
has evolved from 2015 onward, since the introduction of immune checkpoint inhibitors (ICIs) …
has evolved from 2015 onward, since the introduction of immune checkpoint inhibitors (ICIs) …
[HTML][HTML] Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care …
HA Divan, MA Bittoni, A Krishna, DP Carbone - Lung Cancer, 2023 - Elsevier
Objectives Data to guide treatment selection in metastatic nonsquamous (mNSq) non-small
cell lung cancer (NSCLC) after progression on current standard-of-care (SoC) treatment are …
cell lung cancer (NSCLC) after progression on current standard-of-care (SoC) treatment are …
[HTML][HTML] Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network
E Nadler, A Vasudevan, Y Wang, S Ogale - Cancer Treatment and …, 2022 - Elsevier
Background This study investigated biomarker testing and biomarker-guided treatment
among patients with metastatic NSCLC in a real-world setting. Methods This retrospective …
among patients with metastatic NSCLC in a real-world setting. Methods This retrospective …
[HTML][HTML] Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey
H Bailey, A Lee, L Eccles, Y Yuan, H Burlison… - BMC cancer, 2023 - Springer
Background The landscape of non-small cell lung cancer (NSCLC) therapy is rapidly
changing. This analysis aimed to understand patient characteristics, diagnosis and …
changing. This analysis aimed to understand patient characteristics, diagnosis and …
[HTML][HTML] Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for Medicare patients with …
A Arunachalam, H Li, MA Bittoni, R Camacho, X Cao… - Clinical Lung Cancer, 2018 - Elsevier
Introduction Real-world data on current treatment practices for non–small-cell lung cancer
(NSCLC) are needed to understand the place in therapy and potential economic impact of …
(NSCLC) are needed to understand the place in therapy and potential economic impact of …